Association Between Serum Afamin Levels with Nonalcoholic Associated Fatty Liver Disease

Chen, Shenghui; Liu, Zhening; Wang, Jinghua; Zhang, Juanwen; Zhang, Xiaofeng; Xu, Chengfu

doi:10.1155/2022/7175108

Cited by 5 publications

(3 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Higher BMI, WC, WHR and fat mass found in GHU subjects could theoretically explain the higher afamin concentrations, however, afamin correlated only with WC among these parameters in AGHD. Interestingly, AST, a common marker of liver injury ( 21 ), was also found higher in GHU subjects, and consistent with previous studies, positively correlated with afamin levels ( 19 , 22 , 23 ). A former study with larger sample size also detected elevated AST levels (39.3 ± 28.4 IU/L) in unsubstituted AGHD patients.…”

Section: Discussionsupporting

confidence: 91%

Serum afamin and its implications in adult growth hormone deficiency: a prospective GH-withdrawal study

Ratku,

Lőrincz,

Csiha

et al. 2024

Front. Endocrinol.

View full text Add to dashboard Cite

IntroductionAdult growth hormone deficiency (AGHD) is associated with a high prevalence of metabolic syndrome (MS), which contributes to the unfavorable cardiovascular risk profile in these patients. Insulin like growth factor-1 (IGF-1) is a widely used biomarker, however it does not always reflect the cardiometabolic risk and has a poor relationship with clinical efficacy endpoints. Consequently, there is an unmet need for biomarkers to monitor responses to GH-replacement. Afamin is a hormone-like glycoprotein, expressed in the liver. Higher afamin levels are strongly associated with MS and insulin resistance (IR). Although both MS and IR are very common in AGHD, afamin has not been investigated in these patients.PurposeTo investigate afamin as a potential biomarker in patients with AGHD.Materials and methodsParticipants included 20 AGHD patients (11 GH-substituted and 9 GH-unsubstituted) and 37 healthy controls. Subjects underwent routine laboratory examinations, anthropometric measurements, body composition analysis using multi-frequency bioelectrical impedance analysis (InBody720) and measurement of serum afamin concentrations. In GH-substituted subjects, GH-substitution was withdrawn for 2 months. Measurements were carried out right before GH-withdrawal, at the end of the 2-month withdrawal period, and 1 month after reinstituting GH-replacement therapy (GHRT).ResultsGH-unsubstituted patients demonstrated higher afamin levels compared to controls (p=0.03). Afamin positively correlated with skeletal muscle mass, bone mineral content, total body water, extracellular- and intracellular water content, insulin (all, p<0.01), HOMA-IR (p=0.01) and C-peptide (p=0.03) levels in AGHD but not in healthy controls. In GH-substituted patients 2-month of GH-withdrawal caused significant changes in body composition, including decreased fat-free mass, skeletal muscle mass, total body water, and intracellular water content (all, p<0.01); but these changes almost fully recovered 1 month after reinstituting GHRT. Unexpectedly, afamin levels decreased after GH-withdrawal (p=0.03) and increased with reinstitution (p<0.01). Changes of afamin levels during GH-withdrawal positively correlated with changes of HOMA-IR (r=0.80; p<0.01) and changes of insulin (r=0.71; p=0.02).ConclusionHigher afamin levels in unsubstituted AGHD patients might indicate severe metabolic dysregulation. Significant changes accompanying GH-withdrawal and reinstitution, along with strong correlations with measures of IR, suggest that afamin could be a promising biomarker to monitor GHRT-associated changes of insulin sensitivity.

show abstract

Section: Discussionsupporting

confidence: 91%

Serum afamin and its implications in adult growth hormone deficiency: a prospective GH-withdrawal study

Ratku,

Lőrincz,

Csiha

et al. 2024

Front. Endocrinol.

View full text Add to dashboard Cite

show abstract

“…Former studies have reported a strong association of elevated serum afamin with various metabolic disorders, including obesity, MetS, T2DM, NAFLD, and coronary atherosclerosis [ 9 , 28 , 29 ]. In line with these data, in our study, afamin levels were found to be 32.2% higher in the NDO group and nearly two-fold higher in the T2DM group, suggesting that elevated afamin may indicate metabolic disturbance in severe obesity with intact glucose parameters.…”

Section: Discussionmentioning

confidence: 99%

Impaired Organokine Regulation in Non-Diabetic Obese Subjects: Halfway to the Cardiometabolic Danger Zone

Lőrincz

Ratku

Csiha

et al. 2023

IJMS

View full text Add to dashboard Cite

Altered organokine expression contributes to increased cardiometabolic risk in obesity. Our aim was to evaluate the associations of serum afamin with glucose homeostasis, atherogenic dyslipidemia, and other adipokines in severe obesity to clarify the early metabolic alterations. 106 non-diabetic obese (NDO) subjects and 62 obese patients with type 2 diabetes matched for age, gender, and body mass index (BMI) were enrolled in this study. We compared their data with 49 healthy, lean controls. Serum afamin and retinol-binding protein 4 (RBP4), as well as plasma plasminogen activator inhibitor-1 (PAI-1), were measured with ELISA, and lipoprotein subfractions were analyzed using Lipoprint gel electrophoresis. Afamin and PAI-1 found to be significantly higher in the NDO and T2M group (p < 0.001 and p < 0.001, respectively) than in the controls. In contrast, RBP4 was unexpectedly lower in the NDO and T2DM group compared to controls (p < 0.001). Afamin showed negative correlations with mean LDL size and RBP4, but positive correlations with anthropometric, glucose/lipid parameters, and PAI-1 in both the overall patients and the in NDO + T2DM groups. BMI, glucose, intermediate HDL, and small HDL were predictors of afamin. Afamin may serve as a biomarker for the severity of cardiometabolic disturbances in obesity. The complexity of organokine patterns in NDO subjects draws attention to the diverse spectrum of obesity-related comorbidities.

show abstract

“…Despite the fact that the physiological role of AFM is mainly unclear, several studies have discovered a strong correlation between AFM and (obesity, type 2 diabetes mellitus T2DM) [6]. The metabolic syndrome (MetS) and body mass index(BMI) the prevalence of have been reported to be positively correlated with serum afamin levels [7] [8]. Moreover, transgenic mice that overexpress afamin have higher body weights and ( lipoprotein and blood lipid) concentrations [9] [10].…”

Section: Introductionmentioning

confidence: 99%

A Review of Afamin A Metabolic Novel Marker of Many Diseases

Layla

2023

wjps

View full text Add to dashboard Cite

Human plasma vitamin E-binding glycoprotein afamin is mostly produced in the liver and released into the circulation. The review in this study related to a glycoprotein afamin marker that is important in many disease(Type 2 diabetes mellitus,cancer,obesity , Gestational diabetes mellitus,oxidative stress,and metabolic syndrome. Although ovarian follicles and human cerebrospinal fluid also contain sizable amounts of AFM, the liver is the main organ that generates it. Though there are minor AFM manifestations have been also reported in the human heart, testis, brain, kidney, and ovary. Afamin is promising metabolic novel marker for gestational diabetes,type 2 diabetes mellitus cancer,metabolic syndrome,and related disease.

show abstract

Association Between Serum Afamin Levels with Nonalcoholic Associated Fatty Liver Disease

Cited by 5 publications

References 36 publications

Serum afamin and its implications in adult growth hormone deficiency: a prospective GH-withdrawal study

Serum afamin and its implications in adult growth hormone deficiency: a prospective GH-withdrawal study

Impaired Organokine Regulation in Non-Diabetic Obese Subjects: Halfway to the Cardiometabolic Danger Zone

A Review of Afamin A Metabolic Novel Marker of Many Diseases

Contact Info

Product

Resources

About